A Brief Review of Clinical Considerations for Healthcare Provider-Administered Cardiovascular Risk Modifying Medications

Cardiovascular Disease (CVD) remains a major contributor to morbidity and mortality, with effective lipid management being essential in reducing Atherosclerotic Cardiovascular Disease (ASCVD) risk. While statins have long been the primary treatment, barriers such as intolerance, poor adherence, and clinical inertia often prevent patients from achieving optimal Low-Density Lipoprotein Cholesterol (LDL-C) levels. Despite the availability of alternative lipid-lowering therapies (LLTs), many patients still fail to meet recommended targets. The introduction of provider-administered LLTs, like inclisiran, presents a promising strategy to enhance adherence through in-office administration under a "buy-and-bill" model. This approach improves treatment continuity, reduces administrative hurdles, and may alleviate financial constraints, particularly for Medicare beneficiaries. Implementing this model successfully requires coordinated efforts, including provider education, infrastructure development, and streamlined reimbursement processes. As cardiovascular care continues to advance, provider-administered LLTs may play a critical role in improving patient outcomes and mitigating the burden of ASCVD.